http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-538342-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9fb0d6ac247c1e91ab42bf282fa41c3b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_de9d45fb1a5f5c9ca50d75ced2319b60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_65c60a301a05f3fd7dd09aa1bc0e107d |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-12 |
| filingDate | 2003-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e256043b7d57d08e9880498d4fb79dc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d798053e7b80ec55401954182a9f95ed http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14698f43e0be2ed9f5ead14a26b8f3c3 |
| publicationDate | 2007-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-538342-A |
| titleOfInvention | Estrogen replacement regimen |
| abstract | Disclosed is a pharmaceutical preparation, for administration to a female in need of estrogen replacement, comprising a plurality of doses arranged in alternating standard dose estrogen phases and ultra low dose estrogen phases, each phase consisting of from about 1 to about 4 consecutive daily unit doses or an equivalent thereof, wherein the daily unit doses of the standard dose estrogen phases contain an amount of a substance exhibiting estrogenic activity equivalent to from at or about 0.5 mg to at or about 5.0 mg of estradiol, and the daily unit doses of the ultra-low dose estrogen phases contain an amount of a substance exhibiting estrogenic activity equivalent to from at or about 0.005 mg to at or about 0.5 mg of estradiol. The standard dose estrogen phase may contain an amount of a substance exhibiting progestogenic activity equivalent to from 0 mg to at or about 300 mg of micronized progesterone and the ultra-low dose estrogen phase may contain an amount of a substance exhibiting progestogenic activity equivalent to from at or about 50 mg to at or about 300 mg of micronized progesterone. The amount of the substance exhibiting progestogenic activity may be alternately increased in the ultra-low dose estrogen phases to provide daily unit doses exhibiting dominant activity and decreased in the standard dose estrogen phases to provide daily unit doses exhibiting lower progestin activity. |
| priorityDate | 2002-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 194.